PWA
CVS icon

Provenance Wealth Advisors’s CVS Health CVS Stock Holding History

Provenance Wealth Advisors’s Portfolio CVS Stock Details CVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$119K Buy
1,148
+7
+0.6% +$625 0.01% 171
2026
Q1 		$81.9K Buy
1,141
+808
+243% +$62.2K 0.01% 171
2025
Q4 		$26.4K Sell
333
-818
-71% -$64.5K ﹤0.01% 240
2025
Q3 		$86.8K Hold
1,151
– – 0.01% 172
2025
Q2 		$79.4K Sell
1,151
-905
-44% -$59.3K 0.01% 178
2025
Q1 		$139K Sell
2,056
-2,620
-56% -$157K 0.02% 151
2024
Q4 		$210K Sell
4,676
-13,033
-74% -$731K 0.03% 144
2024
Q3 		$1.11M Buy
17,709
+1,768
+11% +$103K 0.14% 62
2024
Q2 		$941K Sell
15,941
-383
-2% -$24K 0.13% 66
2024
Q1 		$1.3M Buy
16,324
+1,448
+10% +$111K 0.18% 48
2023
Q4 		$1.17M Buy
14,876
+390
+3% +$27.8K 0.16% 50
2023
Q3 		$1.01M Buy
+14,486
New +$1.03M 0.16% 50

Other funds holding CVS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Provenance Wealth Advisors's CVS Position: Q2 2026 in Review

Provenance Wealth Advisors increased its CVS Health (CVS) stake by 0.61% in Q2 2026, buying an estimated $625 and bringing the position to 1,148 shares worth $119K. The position accounts for 0.01% of the portfolio, ranked #171.

Provenance Wealth Advisors first reported a position in CVS in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.3M in Q1 2024. 2,061 funds tracked by Wall St. Rank hold CVS as of Q2 2026.

  • Provenance Wealth Advisors held 1,148 shares of CVS Health worth $119K as of Q2 2026.
  • Provenance Wealth Advisors bought 7 CVS Health shares in Q2 2026, an estimated $625.
  • CVS Health made up 0.01% of Provenance Wealth Advisors's portfolio in Q2 2026, its #171 holding.
  • Provenance Wealth Advisors first reported a position in CVS Health in Q3 2023 and has held it in 12 quarters since.
  • Provenance Wealth Advisors's CVS Health position peaked at $1.3M in Q1 2024.
  • 2,061 funds tracked by Wall St. Rank held CVS Health as of Q2 2026.

Based on Provenance Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.